ROCHESTER HILLS, Mich. - InfuSystem Holdings, Inc. (NYSE American: INFU), a provider of health care services, has been notified by the NYSE American LLC of non-compliance with listing standards due to a delay in filing its annual report. The company was to submit its Form 10-K for the year ended December 31, 2023, by April 1, 2024, but failed to meet the deadline.
The delay in filing is attributed to the need for additional time to review potential errors in expense classification and the implementation of new lease accounting standards, ASC 842. InfuSystem disclosed these issues in a late filing notification on March 14, 2024.
NYSE American has granted InfuSystem a six-month cure period, starting from the missed filing date, to submit the overdue report. The exchange will monitor the situation, and the company could receive an additional six-month period to regain compliance. However, if the company does not file within these periods, or if other delisting criteria are met, suspension and delisting procedures could be initiated.
InfuSystem, which operates in the durable medical equipment sector, has expressed its intention to file the necessary documents and regain compliance with the exchange's listing standards. However, there is no guarantee that the company will meet the exchange's requirements in the future.
This announcement is based on a press release statement from InfuSystem Holdings, Inc.
InvestingPro Insights
As InfuSystem Holdings, Inc. navigates through its current challenges with filing compliance, investors may find the latest data from InvestingPro to be of particular interest. According to recent metrics, InfuSystem's revenue growth has shown resilience, with a 14.53% increase in the last twelve months as of Q4 2023. This is complemented by a healthy gross profit margin of 50.17%, indicating the company's ability to maintain profitability in its operations.
From an investment standpoint, two InvestingPro Tips shed light on the company's financial health and market valuation. Firstly, InfuSystem is trading at a low P/E ratio relative to near-term earnings growth, which could suggest that the stock is undervalued compared to its growth potential.
Secondly, analysts predict that the company will be profitable this year, aligning with the positive net income growth expectation.
Investors considering InfuSystem as part of their portfolio may also note that the company does not pay a dividend, which could be a relevant factor for those seeking income-generating investments. For a more comprehensive analysis, there are additional InvestingPro Tips available on InvestingPro, which could further inform investment decisions. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking even more insights into InfuSystem's financials and market standing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.